BTIG Maintains Their Hold Rating on Dexcom (DXCM)


BTIG analyst Marie Thibault maintained a Hold rating on Dexcom (DXCM) on May 16. The company’s shares closed last Monday at $325.40, close to its 52-week low of $305.63.

Dexcom has an analyst consensus of Moderate Buy, with a price target consensus of $463.60.

See today’s analyst top recommended stocks >>

The company has a one-year high of $456.23 and a one-year low of $305.63. Currently, Dexcom has an average volume of 785.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts